Shahab Uddin
Shahab Uddin is an expert in Oncology at Hamad Medical Corporation (Qatar). As of October 2026, ScienceLeadR ranks Shahab Uddin in the top 1% of experts in Qatar for Thyroid Neoplasms, Lymphoma and Lymphoproliferative Disorders. Shahab Uddin has authored 378 publications, the most recent in 2026, and is an investigator in 2 clinical trials. SLR score: 1,376 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Biochemistry - Pharmacy - Hematology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2003 - 2026
Number : 378
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Beyond Structure: The Dynamic Role of the Extracellular Matrix Components in Immune Evasion. PMID 42787254 — cells, chemokines, neoplasms, biomarkers, immunotherapy, fibroblasts, therapeutics, extracellular matrix, immune evasion | Cancer Commun (Lond) | 2026 | 0 |
| The Arabidopsis tex1-4 mutant exhibits altered mRNA export and hormonal crosstalk in plant immunity against Pseudomonas syringae. PMID 42624939 — genes, pseudomonas syringae, pseudomonas, rna, messenger, plant immunity, cytoplasm, immunity, infections | Plant Cell Rep | 2026 | 0 |
| Tumor Plasticity and Microenvironmental Crosstalk as Drivers of Metastasis and Therapy Resistance. PMID 42488707 — cells, microscopy, electron, scanning transmission, neoplasms, neoplasm metastasis, therapeutics, plastics, tumor microenvironment, immune evasion | MedComm (2020) | 2026 | 0 |
| Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies. PMID 42483185 — cells, natural killer t-cells, antibodies, killer cells, natural, macrophages, neoplasms, multiple chronic conditions, biomarkers, multiple myeloma, precision medicine, therapeutics, t-lymphocytes | Front Immunol | 2026 | 0 |
| Pristimerin Suppresses Janus Kinase/Signal Transducers and Activators of Transcription Oncogenic Signaling To Drive Mitochondrial and Caspase-Dependent Apoptosis in Multiple Myeloma. PMID 42453348 — cells, transducers, caspases, multiple myeloma, janus kinases, therapeutics, apoptosis | ACS Pharmacol Transl Sci | 2026 | 0 |
Clinical Studies 2
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
LeadR Networks
Main global connection map